|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Descriptive Information Fields | |||||
| Brief Title † | BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | ||||
| Official Title † | Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas | ||||
| Brief Summary | RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma. PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in treating young patients with relapsed or refractory acute lymphoblastic leukemia or non-Hodgkin's lymphoma. |
||||
| Detailed Description | OBJECTIVES: Primary
Secondary
OUTLINE: This is a non-randomized, dose-escalation study. Patients receive BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses. Cohorts of 3-6 patients receive escalating doses of BL22 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, the cohort is expanded and a total of 12 patients are treated at that dose. Patients are followed weekly for at least 1 month and then every 1-3 months thereafter. PROJECTED ACCRUAL: A total of 95 patients will be accrued for this study. |
||||
| Study Phase | Phase I | ||||
| Study Type † | Interventional | ||||
| Study Design † | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety Study | ||||
| Primary Outcome Measure † | assessment of efficacy, safety, pharmacokinetics, immunogenicity. [ Time Frame: end of study ] [ Designated as safety issue: Yes ] | ||||
| Secondary Outcome Measure † | Expansion of MTD [ Time Frame: end of study ] [ Designated as safety issue: Yes ] | ||||
| Condition † | Leukemia Lymphoma |
||||
| Intervention † | Drug: BL22 immunotoxin Procedure: antibody-drug conjugate therapy Procedure: immunotoxin therapy Procedure: monoclonal antibody therapy |
||||
| MEDLINE PMIDs | |||||
| Links | Clinical trial summary from the National Cancer Institute's PDQ® database ![]() |
||||
| Recruitment Information Fields | |||||
| Recruitment Status † | Suspended | ||||
| Enrollment † | 95 | ||||
| Start Date † | January 2004 | ||||
| Completion Date | October 2008 | ||||
| Eligibility Criteria † | DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Immunologic
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
|
||||
| Gender | Both | ||||
| Ages | 6 Months to 24 Years | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts †† | |||||
| Location Countries † | United States | ||||
| Administrative Information Fields | |||||
| NCT ID † | NCT00077493 | ||||
| Organization ID | CDR0000352020 | ||||
| Secondary IDs †† | NCI-04-C-0079H, NCI-5643 | ||||
| Study Sponsor † | MedImmune LLC | ||||
| Collaborators †† | Cambridge Antibody Technology | ||||
| Investigators † |
|
||||
| Information Provided By | MedImmune LLC | ||||
| Verification Date | December 2007 | ||||
| First Received Date † | February 10, 2004 | ||||
| Last Updated Date | December 21, 2007 | ||||